AR096235A1 - Arilquinazolinas - Google Patents

Arilquinazolinas

Info

Publication number
AR096235A1
AR096235A1 ARP140101881A ARP140101881A AR096235A1 AR 096235 A1 AR096235 A1 AR 096235A1 AR P140101881 A ARP140101881 A AR P140101881A AR P140101881 A ARP140101881 A AR P140101881A AR 096235 A1 AR096235 A1 AR 096235A1
Authority
AR
Argentina
Prior art keywords
hal
atoms
het2
independently
replaced
Prior art date
Application number
ARP140101881A
Other languages
English (en)
Inventor
Dr Buchstaller Hans
W K R Peter - Dr Mederski Werner
Dr Emde Ulrich
Dr Fuchss Thomas
Original Assignee
Merck Patent Ges Mit Beschränkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50729442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR096235(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Ges Mit Beschränkter Haftung filed Critical Merck Patent Ges Mit Beschränkter Haftung
Publication of AR096235A1 publication Critical patent/AR096235A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/02—Monocyclic aromatic halogenated hydrocarbons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

La presente se refiere a compuestos de la fórmula (1), que se pueden usar para la inhibición de serina treonina proteína quinasas, así como para la sensibilización de células cancerosas ante agentes anticáncer y/o radiación ionizante. Reivindicación 1: Compuestos de la fórmula (1) en donde X es CH, CF, S o N; Y es CH, S o N; Z es C o N; - - - - forma, cuando Z = C, junto con el enlace simple un enlace doble, está ausente cuando Z = N; n es 1 ó 2, en donde cuando n = 1, X = S, y cuando n = 2, ambos son X = CH o X unido con el anillo pirimidina es CF y X no unido con el anillo pirimidina es CH o un X es CH y el otro X es N; m es 1 ó 2, en donde cuando m = 1, Y = S, y cuando m = 2, ambos son Y = CH o un Y es CH y el otro Y es N; R¹, R², R³, R⁴ son, de modo independiente entre sí, H, Hal, CN, OH, CONH₂, CONH(LA) o LA; R⁵ es H, Hal, CN o CºCH; Cyc es fenilo, que no está sustituido o que puede estar mono- o disustituido, de modo independiente entre sí, con R⁶ o es Het¹; Het¹ es un heterociclo de 5 - 10 miembros mono- o bicíclico, con 1 - 3 átomos de N, O y/o S o 1 - 4 átomos de N, que no está sustituido o que puede estar mono-, di- o trisustituido, de modo independiente entre sí, con R⁶ o que puede estar monosustituido con Het²; R⁶ es Hal, LA, oxo, CN o NH₂; LA es alquilo no ramificado o ramificado con 1 - 5 átomos de C, que puede estar saturado o parcialmente insaturado, en donde 1 - 3 átomos de H pueden estar reemplazados por Hal, y/o un átomo de H puede estar reemplazado por CN o Het², y/o uno o dos grupos CH₂ pueden estar reemplazados por O, NH, NH₂, N(CH₃) o CO; Het² es un homo- o heterociclo alifático de 3 - 5 miembros con 0, 1, 2 ó 3 átomos de N, O y/o S, que no está sustituido; Hal es F, Cl, Br o I; y/o sus sales, tautómeros y/o esteroisómeros fisiológicamente inocuos, incluyendo sus mezclas en todas las proporciones.
ARP140101881A 2013-05-11 2014-05-09 Arilquinazolinas AR096235A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102013008118.1A DE102013008118A1 (de) 2013-05-11 2013-05-11 Arylchinazoline

Publications (1)

Publication Number Publication Date
AR096235A1 true AR096235A1 (es) 2015-12-16

Family

ID=50729442

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140101881A AR096235A1 (es) 2013-05-11 2014-05-09 Arilquinazolinas
ARP220100052A AR124607A2 (es) 2013-05-11 2022-01-12 Arilquinazolinas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP220100052A AR124607A2 (es) 2013-05-11 2022-01-12 Arilquinazolinas

Country Status (32)

Country Link
US (5) US9732094B2 (es)
EP (1) EP2994467B1 (es)
JP (1) JP6562903B2 (es)
KR (1) KR102292811B1 (es)
CN (1) CN105358552B (es)
AR (2) AR096235A1 (es)
AU (1) AU2014267723B2 (es)
BR (1) BR112015027951B1 (es)
CA (1) CA2911668C (es)
CL (1) CL2015003285A1 (es)
DE (1) DE102013008118A1 (es)
DK (1) DK2994467T3 (es)
ES (1) ES2693774T3 (es)
HK (1) HK1221719A1 (es)
HR (1) HRP20181775T1 (es)
HU (1) HUE041397T2 (es)
IL (2) IL242348B (es)
LT (1) LT2994467T (es)
MX (1) MX362183B (es)
MY (1) MY173126A (es)
NZ (1) NZ713362A (es)
PE (1) PE20152001A1 (es)
PH (1) PH12015502339A1 (es)
PL (1) PL2994467T3 (es)
PT (1) PT2994467T (es)
RS (1) RS57838B1 (es)
RU (1) RU2701193C2 (es)
SG (1) SG11201509268YA (es)
SI (1) SI2994467T1 (es)
TR (1) TR201816069T4 (es)
UA (1) UA116020C2 (es)
WO (1) WO2014183850A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
EP4279087A3 (en) 2015-02-26 2024-01-31 Merck Patent GmbH Pd-1 / pd-l1 inhibitors for the treatment of cancer
MX2017016324A (es) 2015-06-16 2018-03-02 Merck Patent Gmbh Tratamientos de combinacion de antagonista de ligando 1 de muerte programada (pd-l1).
WO2017166104A1 (en) * 2016-03-30 2017-10-05 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
CA3039451A1 (en) 2016-10-06 2018-04-12 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
EP3554495A1 (en) * 2016-12-19 2019-10-23 Merck Patent GmbH Combination of a protein kinase inhibitor and an additional chemotherapeutic agent
KR102644408B1 (ko) * 2017-03-30 2024-03-07 메르크 파텐트 게엠베하 암의 치료를 위한 항-pd-l1 항체 및 dna-pk 억제제의 병용
MX2019011639A (es) * 2017-03-30 2019-12-05 Merck Patent Gmbh Formulacion farmaceutica.
EP3601265B1 (en) 2017-03-30 2023-06-21 Merck Patent GmbH Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
WO2018178129A1 (en) 2017-03-30 2018-10-04 Merck Patent Gmbh Crystalline form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
JP7391854B2 (ja) * 2018-01-17 2023-12-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｄｎａ－ｐｋ阻害剤
TW202014201A (zh) * 2018-05-04 2020-04-16 德商馬克專利公司 用於治療癌症之ＰＤ-１／ＰＤ-Ｌ１，ＴＧＦβ及ＤＮＡ-ＰＫ之組合抑制
US11084829B2 (en) * 2018-09-24 2021-08-10 Rapt Therapeutics, Inc. Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof
EP3911330A1 (en) 2018-12-21 2021-11-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Dna-pkcs inhibitors for increasing genome editing efficiency
CN111909144A (zh) * 2019-05-10 2020-11-10 山东轩竹医药科技有限公司 喹唑啉类dna-pk抑制剂
US20220267310A1 (en) * 2019-06-27 2022-08-25 Medshine Discovery Inc. Quinazoline and cinnoline derivatives as dna-pk inhibitor
CN112300132A (zh) * 2019-07-30 2021-02-02 山东轩竹医药科技有限公司 芳基喹唑啉类dna-pk抑制剂
WO2022058323A1 (en) 2020-09-18 2022-03-24 Merck Patent Gmbh Compounds for the treatment of viral infections
EP4229415A1 (en) * 2020-10-19 2023-08-23 Baruch S. Blumberg Institute Methods and kits for diagnosing and treating cancers
TW202229281A (zh) * 2020-12-24 2022-08-01 大陸商江蘇恆瑞醫藥股份有限公司 嘌呤酮類化合物、其製備方法及其在醫藥上的應用
WO2022143671A1 (zh) * 2020-12-28 2022-07-07 南京明德新药研发有限公司 吗啉取代的苯并嘧啶类化合物的晶型及其制备方法
CR20230535A (es) 2021-04-17 2024-02-16 Intellia Therapeutics Inc Inhibidores de proteína cinasa dependiente de adn y composiciones y usos de estos
CN115557900B (zh) * 2022-11-11 2024-03-15 常州大学 一种3-取代哒嗪衍生物的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK400992A3 (en) 1990-11-06 1995-08-09 Pfizer Quinazolines derivatives for enhancing antitumor activity
CN1169527A (zh) * 1996-06-24 1998-01-07 考克库姆·索尼克斯公司 低频声的声发射器
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
UA71555C2 (en) * 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
WO2000061186A1 (en) 1999-04-08 2000-10-19 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP2013206A1 (en) * 2006-04-25 2009-01-14 Astex Therapeutics Limited Pharmaceutical compounds
AR060632A1 (es) * 2006-04-26 2008-07-02 Genentech Inc Compuestos inhibidores de fosfoinositida 3- quinasa y metodos de uso
PL2057156T3 (pl) * 2006-08-23 2017-08-31 Kudos Pharmaceuticals Limited Pochodne 2-metylomorfolinowe pirydo-, pirazo- i pirymido-pirymidyny jako inhibitory mTOR
RU2470936C2 (ru) * 2006-12-07 2012-12-27 Дженентек, Инк. Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения
JP2011502141A (ja) * 2007-10-29 2011-01-20 ナトコ ファーマ リミテッド 抗癌剤としての４‐（テトラゾール‐５‐イル）‐キナゾリン誘導体
WO2010008739A2 (en) 2008-06-20 2010-01-21 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
EP2408454A2 (en) * 2009-03-18 2012-01-25 Resverlogix Corp. Novel anti-inflammatory agents
CA2755251A1 (en) 2009-03-18 2010-09-23 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
WO2011113512A1 (de) * 2010-03-16 2011-09-22 Merck Patent Gmbh Morpholinylchinazoline
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
JP2013538800A (ja) 2010-08-10 2013-10-17 アッヴィ・インコーポレイテッド 新規ｔｒｐｖ３モジュレーター
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
DE102011118830A1 (de) 2011-11-18 2013-05-23 Merck Patent Gmbh Morpholinylbenzotriazine
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
EP2892534B8 (en) 2012-09-06 2021-09-15 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
AU2014295000A1 (en) 2013-07-25 2016-02-18 Fondazione Telethon Inhibitors of FAPP2 and uses thereof
EP3554495A1 (en) * 2016-12-19 2019-10-23 Merck Patent GmbH Combination of a protein kinase inhibitor and an additional chemotherapeutic agent
MX2019011639A (es) * 2017-03-30 2019-12-05 Merck Patent Gmbh Formulacion farmaceutica.
EP3601265B1 (en) * 2017-03-30 2023-06-21 Merck Patent GmbH Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
WO2018178129A1 (en) * 2017-03-30 2018-10-04 Merck Patent Gmbh Crystalline form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol

Also Published As

Publication number Publication date
IL285390A (en) 2021-09-30
WO2014183850A1 (de) 2014-11-20
BR112015027951B1 (pt) 2022-05-31
US10172859B2 (en) 2019-01-08
US20190142833A1 (en) 2019-05-16
HK1221719A1 (zh) 2017-06-09
ES2693774T3 (es) 2018-12-13
US11065253B2 (en) 2021-07-20
US20220117970A1 (en) 2022-04-21
MY173126A (en) 2019-12-30
JP6562903B2 (ja) 2019-08-21
US10383874B2 (en) 2019-08-20
AR124607A2 (es) 2023-04-12
SG11201509268YA (en) 2015-12-30
MX2015015512A (es) 2016-02-05
MX362183B (es) 2019-01-08
EP2994467B1 (de) 2018-08-01
KR102292811B1 (ko) 2021-08-23
LT2994467T (lt) 2018-11-12
PH12015502339B1 (en) 2016-02-22
EP2994467A1 (de) 2016-03-16
PE20152001A1 (es) 2016-01-13
KR20160006231A (ko) 2016-01-18
US20170290836A1 (en) 2017-10-12
PT2994467T (pt) 2018-11-16
US20200069690A1 (en) 2020-03-05
CL2015003285A1 (es) 2016-05-27
IL242348B (en) 2022-01-01
AU2014267723A1 (en) 2015-12-24
CA2911668C (en) 2021-07-06
BR112015027951A2 (pt) 2017-07-25
AU2014267723B2 (en) 2018-05-31
CN105358552A (zh) 2016-02-24
RU2015153094A3 (es) 2018-03-26
TR201816069T4 (tr) 2018-11-21
RU2701193C2 (ru) 2019-09-25
CA2911668A1 (en) 2014-11-20
RS57838B1 (sr) 2018-12-31
NZ713362A (en) 2020-09-25
HUE041397T2 (hu) 2019-05-28
US9732094B2 (en) 2017-08-15
UA116020C2 (uk) 2018-01-25
SI2994467T1 (sl) 2018-12-31
RU2015153094A (ru) 2017-06-16
CN105358552B (zh) 2018-04-27
HRP20181775T1 (hr) 2018-12-28
JP2016522190A (ja) 2016-07-28
DK2994467T3 (en) 2018-10-29
BR112015027951A8 (pt) 2019-12-24
PL2994467T3 (pl) 2019-03-29
US20160083401A1 (en) 2016-03-24
PH12015502339A1 (en) 2016-02-22
DE102013008118A1 (de) 2014-11-13

Similar Documents

Publication Publication Date Title
AR096235A1 (es) Arilquinazolinas
AR092211A1 (es) Derivados de hidropirrolopirrol
AR092365A1 (es) Derivados de piridopirimidina
AR080757A1 (es) Morfolinilquinazolinas, procesos de obtencion, intermediarios, usos y composiciones farmaceuticas.
AR082728A1 (es) Imidazolonilquinolinas utiles para tratar el cancer, composiciones farmaceuticas que las contienen, proceso de sintesis, intermediarios de dicha sintesis y procedimiento para prepararlos
AR089944A1 (es) Derivados de tetrahidro-quinazolinona
AR090602A1 (es) AMIDAS CICLICAS Y HETEROCICLOS COMO INHIBIDORES DE MetAP-2
AR100645A1 (es) Derivados de pirazolo-pirimidina
CL2015002520A1 (es) Compuestos novedosos de pirimidina y piridina y su uso.
AR066543A1 (es) Derivados de piridazinona
AR081828A1 (es) Compuestos de biguanida y su uso para el tratamiento del cancer
AR092670A1 (es) Derivados de quinazolinona
AR097866A1 (es) Derivados de 4-azaindol
AR094784A1 (es) Compuestos de tubulisina, métodos para obtenerlos y uso
AR094342A1 (es) Derivados de ácido borónico útiles como agentes antimicrobianos
AR094313A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR097087A1 (es) Derivados de oxoquinazolinil-butanamida
AR082726A1 (es) Derivados de triazolopirazina
AR078313A1 (es) Derivados de piridinil-imidazolona inhibidores de quinasas pi3k,composiciones farmaceuticas que los comprenden, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes e inflamatorias, entre otras
AR097086A1 (es) Derivados 1,3-disustituidos de ciclopentano
AR068658A1 (es) Derivados de tiazol
AR051623A1 (es) Derivados de piridopirimidinona
AR082727A1 (es) Derivados de furopiridina, procesos de preparacion y composiciones farmaceuticas que los contienen
AR109296A1 (es) Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat)
AR100333A1 (es) Derivados de heterociclil-butanamida

Legal Events

Date Code Title Description
FG Grant, registration